De-Escalation of Antiplatelet Treatment in Patients with Myocardial Infarction Who Underwent Percutaneous Coronary Intervention: A Review of the Current Literature
In acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI), treatment with the P2Y<sub>12</sub> inhibitors ticagrelor or prasugrel is recommended over clopidogrel due to a better efficacy, albeit having more bleeding complication. These higher bleeding...
Main Authors: | Daniel MF Claassens, Dirk Sibbing |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-09-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/9/9/2983 |
Similar Items
-
Impact of Routine Platelet Reactivity Testing with VerifyNow Assay on Antiplatelet Choice After Percutaneous Coronary Intervention
by: Mshelbwala FS, et al.
Published: (2020-04-01) -
Возможности замены одного антиагрегантного препарата на другой у пациентов, получающих двойную антиагрегантную терапию
by: A. N. Yakovlev
Published: (2018-04-01) -
Clopidogrel resistance: The way forward
by: Shuvanan Ray
Published: (2014-09-01) -
Platelet inhibition during ticagrelor monotherapy versus ticagrelor plus aspirin in patients with coronary artery disease (TEMPLATE study): study protocol for a randomised controlled trial
by: Sarah Baos, et al.
Published: (2017-11-01) -
Clopidogrel in the treatment of patients with ST-elevation acute myocardial infarction: state-of-art in 2013
by: O. V. Averkov
Published: (2013-02-01)